Top Page
Argent Biopharma
(Sydney:RGT)
Argent Biopharma (RGT) vs. iShares MSCI Australia ETF (EWA)
Argent Biopharma Business Overview & Revenue Model
Argent Biopharma Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 583.45K | 891.08K | 3.39M | 4.73M |
| Gross Profit | 446.32K | 203.70K | 1.45M | 1.81M |
| EBITDA | -17.00M | -15.77M | -20.04M | -16.70M |
| Net Income | -17.84M | -17.53M | -20.82M | -16.77M |
Balance Sheet | ||||
| Total Assets | 2.47M | 10.79M | 9.88M | 23.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 702.87K | 239.82K | 1.79M |
| Total Debt | 8.29M | 1.04M | 575.14K | 4.39M |
| Total Liabilities | 11.10M | 16.61M | 18.02M | 13.66M |
| Stockholders Equity | -8.63M | -5.15M | -7.51M | 11.23M |
Cash Flow | ||||
| Free Cash Flow | -9.28M | -14.40M | -11.26M | -14.85M |
| Operating Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | 208.83K | -140.12K | 51.75K | -2.44M |
| Financing Cash Flow | 9.39M | 14.87M | 9.31M | 9.74M |
Argent Biopharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$12.81M | -1.25 | -140.35% | ― | ― | ― | |
41 Neutral | AU$5.98M | -1.62 | -44.35% | ― | -18.70% | 20.83% | |
40 Underperform | AU$3.96M | ― | 258.94% | ― | ― | ― | |
37 Underperform | AU$13.03M | -0.50 | 459.94% | ― | -2.82% | 32.47% |
Argent Biopharma Corporate Events
Argent BioPharma has dispatched documentation for a General Meeting of shareholders scheduled for 10:00 a.m. AWST on 8 April 2026 in Subiaco, Western Australia. Shareholders are encouraged to participate either in person or by lodging proxies online by 10:00 a.m. AWST on 6 April 2026, with options to manage their meeting-related document preferences through the company’s share registry services.
The convening of the General Meeting signals an ongoing engagement with Argent BioPharma’s investor base as it advances its clinical pipeline and maintains governance processes. While specific resolutions are not detailed in the materials, the meeting framework underscores routine corporate oversight and offers stakeholders formal channels to influence company decisions and stay aligned with its strategic direction.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and confirmed that these securities can be freely traded under the exemption provisions of section 708A(5) of the Corporations Act 2001. The company stated that the shares were issued without a prospectus, affirmed its compliance with applicable financial reporting and continuous disclosure obligations, and said there is no undisclosed information that investors would reasonably require to assess its financial position, prospects or the rights attached to the new shares.
This move supports Argent BioPharma’s capital structure while signalling adherence to Australian corporate governance and disclosure standards, potentially reinforcing investor confidence in its regulatory standing. By clarifying that the new shares qualify for on-sale without additional disclosure and that no material information has been withheld, the company reduces legal uncertainty for secondary trading and underpins liquidity for existing and new shareholders.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited has applied for quotation of 1,000,000 ordinary fully paid shares on the Australian Securities Exchange under the code RGT. The newly quoted securities, issued on February 27, 2026, modestly expand the company’s listed share capital and may incrementally increase liquidity and broaden its shareholder base, though the announcement provides no additional detail on the purpose or terms of the issuance.
The move indicates ongoing capital markets activity by Argent Biopharma as it manages its funding and equity structure. For existing and prospective investors, the additional shares represent a small dilution but also a potential enhancement to trading depth and price discovery in the stock, depending on market demand for the new securities.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma reported interim revenue of $171,499 for the half year to 31 December 2025, a sharp rise from $4,283 a year earlier, while cutting its net loss attributable to members to $2.94 million from $12.16 million. The company did not declare any dividends and continues to carry negative net tangible assets per share of 0.1 cents, underlining its early-stage profile and limited balance sheet strength.
During the period, Argent liquidated its Slovenian subsidiary, Argent BioPharma d.o.o., booking a statutory loss on liquidation of $55,395 as part of a strategic decision to exit that operation. The interim accounts were reviewed without a modified audit opinion but included an emphasis of matter around going concern, signaling ongoing uncertainty about the group’s ability to sustain operations without additional support or improved performance.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has filed a U.S. provisional patent application for its NanoBodies platform, securing priority protection for proprietary peptide targets and nanobody constructs aimed at vascular and peptide-mediated signalling in septic shock and systemic inflammatory disorders. The programme, which will be evaluated in a cecal ligation and perforation septic shock model, is intended to work upstream of cytokine activation and complements CimetrA’s cytokine-modulating mechanism, broadening the company’s neuro-immune strategy and strengthening its long-term U.S.-centred intellectual property position in immune and inflammatory markets.
By expanding its immune-modulatory portfolio beyond cytokine regulation into upstream signalling control, Argent BioPharma is deepening its scientific differentiation in acute inflammatory conditions such as septic shock. Management highlights that the NanoBodies initiative enhances internal R&D capabilities, reinforces the structural depth of the pipeline, and may provide additional therapeutic leverage in addressing complex vascular and immune pathways relevant to severe systemic inflammation.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has issued 2,557,450 fully paid ordinary shares and confirmed that these were made without a prospectus under the disclosure exemptions of Australia’s Corporations Act. The company stated it remains compliant with its financial reporting and continuous disclosure obligations and that there is no undisclosed information materially affecting investors’ ability to assess its financial position or the rights attached to the new shares, supporting orderly secondary trading of the securities.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited has applied to the ASX for quotation of 2,557,450 new ordinary fully paid shares. The securities are being issued as consideration for purchase order reimbursement, reflecting a non-cash settlement structure with counterparties.
The new shares, dated 10 February 2026, will expand Argent Biopharma’s quoted capital base on the ASX. This issuance may modestly dilute existing shareholders while enhancing the company’s financial flexibility by conserving cash for operational needs.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and notified the market that these securities qualify for on‑sale without a prospectus under section 708A(5) of the Corporations Act. The company affirmed it is compliant with its financial reporting and continuous disclosure obligations and stated there is no undisclosed information that would be material to investors’ assessment of its financial position, prospects, or the rights attached to the newly issued shares, helping to maintain transparency and liquidity in its stock.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited, listed on the ASX under the code RGT, has applied for quotation of an additional 1,000,000 ordinary fully paid shares. The new securities, issued on 15 January 2026 following the exercise or conversion of existing options or other convertible instruments, will expand Argent Biopharma’s listed share capital, modestly increasing liquidity and potentially enabling the company to further support its funding and operational needs.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent Biopharma Limited has notified the ASX of its intention to issue up to 20 million new fully paid ordinary shares in a proposed placement, with an expected issue date of 16 March 2026. The additional securities, to be quoted on the ASX subject to the exchange’s agreement, represent a capital-raising move that is likely aimed at strengthening the company’s balance sheet and providing funding flexibility for its ongoing biopharmaceutical activities, with potential implications for existing shareholders through equity dilution and for the company’s capacity to advance its pipeline.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
Argent BioPharma has signed a binding agreement with AusCann Group Holdings to acquire AusCann’s 48% equity stake in CannPal Animal Therapeutics for A$2 million in Argent shares, in a streamlined deal that replaces a broader prior term sheet and excludes AusCann’s EuroCann holding. The transaction, backed by Argent’s board, major shareholders and primary financier C/M Capital Partners, is designed to strengthen Argent’s clinical pipeline by providing validated preclinical and real-world data to accelerate regulatory and commercial progress for its CannEpil® cannabinoid therapy, enhance its intellectual property portfolio through an option to acquire the Neuvis® drug-delivery platform, and support early-access and named-patient programs as well as its U.S. dual-listing and partnering strategy, while also prompting board changes to align governance with the company’s next phase of growth.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.